Endovascular therapy of thoracic aneurysms: Gore TAG trial results.
Although many thoracic endografts are commercially available in Europe, only three such devices have been introduced to the United States. Gore TAG endoprosthesis was the first to enter clinical trials in the United States for treatment of descending thoracic aortic aneurysm, and gained the approval of the US Food and Drug Administration for general use in March 2005. Through clinical trials, the safety and efficacy of the Gore TAG endoprosthesis were proven and shown to be superior to those of open surgical repair. This article details the device and results of these trials.
Cho
Jae-Sung
JS
Division of Vascular Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. chojs@upmc.edu
Haider
Shan-E-Ali
SE
Makaroun
Michel S
MS
D000368:Aged; D000792:Angiography; D017545:Aortic Aneurysm, Thoracic / Q000628:therapy*; D001807:Blood Vessel Prosthesis; D002404:Catheterization / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007902:Length of Stay; D008297:Male; D011138:Polytetrafluoroethylene; D011183:Postoperative Complications / Q000209:etiology* / Q000401:mortality; D011446:Prospective Studies; D011474:Prosthesis Design; D020760:Spinal Cord Ischemia / Q000209:etiology*; D020521:Stroke / Q000209:etiology*; D016019:Survival Analysis
D011138:Polytetrafluoroethylene